Advertisement

Treatment with combination of pioglitazone and glimepiride decreases levels of chemerin and asymmetric dimethylarginine (ADMA) in obese type 2 diabetic patients

  • Ahmed A. Youssef
  • Eman T. Mehanna
  • Omnia I. Ezzat
  • Dina M. Abo-Elmatty
  • Hussein Al-Sawaf
Original Article

Abstract

Chemerin is an adipokine that plays a crucial role in adipocyte differentiation and development, as well as in glucose and lipid metabolism. High levels of asymmetric dimethylarginine (ADMA), a naturally occurring product of metabolism, inhibit nitric oxide (NO) synthesis and are related to endothelial dysfunction. The aim of this study was to investigate the effect of vildagliptin therapy and the combination of pioglitazone and glimepiride on the levels of NO, ADMA, and chemerin in diabetic patients. The study was conducted on 140 subjects, including 40 apparently healthy subjects, and 100 type 2 diabetic obese patients; 50 of them were treated with vildagliptin, and the other 50 patients revived combination of pioglitazone and glimepiride, both groups were treated for 12 months. For all participants, the levels of fasting blood glucose (FBG), fructosamine, HbA1c, lipid profile, ADMA, NO, and chemerin were determined. The levels of those parameters were compared before and after treatment. In both treated groups, levels of FBG, fructosamine, HbA1c, TC, and LDL-C decreased after treatment. Levels of chemerin and ADMA decreased significantly after treatment, whereas the levels of NO increased compared to the baseline values. Additionally, levels of chemerin and ADMA in the group treated with combination of pioglitazone and glimepiride were significantly lower compared to the group treated with vildagliptin. In conclusion, treatment with combination of pioglitazone and glimepiride had a favorable effect on chemerin and ADMA levels in obese type 2 diabetic patients.

Keywords

Asymmetric dimethylarginine Chemerin Nitric oxide Obesity Type 2 diabetes mellitus 

Abbreviations

ADMA

Asymmetric dimethylarginine

BMI

Body mass index

FBG

Fasting blood glucose

HbA1c

Glycated hemoglobin

HDL-C

High-density lipoprotein cholesterol

LDL-C

Low-density lipoprotein cholesterol

NO

Nitric oxide

NOS

Nitric oxide synthase

PPARγ

Proliferator-activated receptor gamma

T2DM

Type 2 diabetes mellitus

TAG

Triacylglycerols

TC

Total cholesterol

TZD

Thiazolidinedione

Notes

Acknowledgements

The authors are thankful to the staff members of the outpatients’ clinic of diabetes in Suez Hospitals for their help in collection of samples.

Authors’ contributions

All authors have contributed significantly to the study. Dina M. Abo-Elmatty and Hussein Al-Sawaf designed the study. Ahmed A. Youssef and Omnia I Ezzat were responsible for collection of samples and laboratory work. Eman T. Mehanna was responsible for data analysis. Ahmed A. Youssef and Eman T. Mehanna wrote the manuscript. This work was funded by the authors.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The present study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the Suez Canal University Research Ethics Committee (code # 201611MH2).

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Mahmuda F, Akhter M, Nath RK. Obesity in the pathogenesis of type 2 diabetes. KYAMC J. 2017;4:357–61.CrossRefGoogle Scholar
  2. 2.
    Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:4711.CrossRefPubMedGoogle Scholar
  4. 4.
    Blüher M. Adipokines—removing road blocks to obesity and diabetes therapy. Mol Metab. 2014;3:230–40.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Piya MK, McTernan PG, Kumar S. Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216:T1–T15.CrossRefPubMedGoogle Scholar
  6. 6.
    Ekpe EE, Ekpe VE. Chemical pathology of chemerin and its link to obesity and type 2 diabetes mellitus: a review. Biochem Mol Biol. 2017;2:37–9.CrossRefGoogle Scholar
  7. 7.
    Neuparth MJ, Proença JB, Santos-Silva A, Coimbra S. Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese Portuguese patients with type 2 diabetes. ISRN Obes. 2013;2013:142097.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Flehmig G, Scholz M, Klöting N, Fasshauer M, Tönjes A, Stumvoll M, et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation. PLoS One. 2014;9:e99785.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Brinkmann SJ, Wörner EA, Leeuwen PA. Strict glucose control and artificial regulation of the NO–ADMA–DDAH system in order to prevent endothelial dysfunction. J Physiol. 2016;594:2775–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Brinkmann SJ, de Boer MC, Buijs N, van Leeuwen PA. Asymmetric dimethylarginine and critical illness. Curr Opin Clin Nutr Metab Care. 2014;17:90–7.PubMedGoogle Scholar
  11. 11.
    Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16:403–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs. 2014;74:587–610.CrossRefPubMedGoogle Scholar
  13. 13.
    Derosa G, Ragonesi PD, Carbone A, Fogari E, D’Angelo A, Cicero AF, et al. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother. 2012;13:2581–91.CrossRefPubMedGoogle Scholar
  14. 14.
    Hu W, Yu Q, Zhang J, Liu D. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation. 2012;35:1287–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Schleicher ED, Vogt BW. Standardization of serum fructosamine assays. Clin Chem. 1990;36:136–9.PubMedGoogle Scholar
  17. 17.
    Chaea SY, Lee M, Kim SW, Bae YH. Protection of insulin secreting cells from nitric oxide induced cellular damage by cross linked hemoglobin. Biomaterials. 2004;25:843–50.CrossRefGoogle Scholar
  18. 18.
    Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest. 2015;21:57–74.Google Scholar
  19. 19.
    Cheon DY, Kang JG, Lee SJ, Ihm SH, Lee EJ, Choi MG, et al. Serum chemerin levels are associated with visceral adiposity, independent of waist circumference, in newly diagnosed type 2 diabetic subjects. Yonsei Med J. 2017;58:319–25.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fülöp P, Seres I, Lőrincz H, Harangi M, Somodi S, Paragh G. Association of chemerin with oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol Med. 2014;18:1313–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. J Diabetes Investig. 2014;5:327–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Yu S, Zhang Y, Li MZ, Xu H, Wang Q, Song J, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J. 2012;125:3440–4.PubMedGoogle Scholar
  23. 23.
    Yamagishi S, Ueda S, Nakamura K, Matsui T, Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des. 2008;14:2613–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Pereira EC, Ferderbar S, Bertolami MC, Faludi AA, Monte O, Xavier HT, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem. 2008;41:1454–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010;7:e1000278.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Ali OA, Chapman M, Nguyen TH, Chirkov YY, Heresztyn T, Mundisugih J, et al. Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve. Heart. 2014;100:800–5.CrossRefPubMedGoogle Scholar
  27. 27.
    de Giorgis T, Marcovecchio ML, Giannini C, Chiavaroli V, Chiarelli F, Mohn A. Blood pressure from childhood to adolescence in obese youths in relation to insulin resistance and asymmetric dimethylarginine. J Endocrinol Investig. 2016;39:169–76.CrossRefGoogle Scholar
  28. 28.
    Baum C, Johannsen SS, Zeller T, Atzler D, Ojeda FM, Wild PS, et al. ADMA and arginine derivatives in relation to non-invasive vascular function in the general population. Atherosclerosis. 2016;244:149–56.CrossRefPubMedGoogle Scholar
  29. 29.
    Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82–90.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016;8:26.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes. 2007;56:3006–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA, et al. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Des Devel Ther. 2014;8:239–43.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547–54.CrossRefPubMedGoogle Scholar
  34. 34.
    Kulkarni KB, Gade PR, Muglikar AG, Bhavthankar SS. A study of glimepiride versus metformin plus glimepiride with respect to glycemic control and lipid profile in type II diabetes mellitus patients. MedPulse – Int Med J. 2016;3:88–91.Google Scholar
  35. 35.
    Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res. 2005;28:255–62.CrossRefPubMedGoogle Scholar
  36. 36.
    Tahara N, Yamagishi SI, Mizoguchi M, Tahara A, Imaizumi T. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glucose tolerance or type 2 diabetes. Rejuvenation Res. 2013;16:344–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Vernochet C, Peres SB, Davis KE, McDonald ME, Qiang L, Wang H, et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol. 2009;29:4714–28.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Research Society for Study of Diabetes in India 2018

Authors and Affiliations

  1. 1.Department of Biochemistry, Faculty of PharmacyEgyptian Russian UniversityCairoEgypt
  2. 2.Department of Biochemistry, Faculty of PharmacySuez Canal UniversityIsmailiaEgypt

Personalised recommendations